A Phase 2 clinical research study is evaluating an investigational treatment for people living with rare chronic kidney diseases — including focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), and minimal change disease (MCD).
Investigating a new treatment that targets rare kidney disease.
This Phase 2 clinical study is testing a new treatment for people living with rare chronic kidney diseases that cause protein to leak into the urine. The goal of this study is to find out whether this treatment can reduce that protein leakage and help protect kidney function.
The study includes four separate groups, one for each condition being researched: focal segmental glomerulosclerosis (FSGS), immunoglobulin A nephropathy (IgAN), membranous nephropathy (MN), and minimal change disease (MCD). This allows researchers to study the treatment across multiple conditions at the same time.
All study-related care, procedures, and treatments are provided at no cost to participants.
Clinical trial opportunity for a new investigational treatment that is not yet available outside of clinical studies — one that works differently from currently approved treatments.
Receive ongoing care from kidney specialists throughout the study — including regular lab work and tests to track how your kidneys are doing.
All study-related visits, procedures, lab tests, imaging, and the investigational treatment are provided at no charge. No insurance is required to participate. You may be reimbursed for travel related expenses.
Your participation directly contributes to the understanding of rare chronic kidney diseases and helps advance a potential disease-modifying treatment that targets the kidneys to reduce protein in the urine and slow the progression of chronic kidney disease.
A condition where small scars form inside the kidney's tiny filtering units. This causes protein to leak into the urine and damage the kidneys. FSGS can be difficult to treat and may progress to kidney failure.
A condition where tiny protein deposits build up inside the kidneys. Over time, this leads to inflammation and scarring that can damage the kidneys, resulting in protein leaking into the urine, and a gradual loss of kidney function.
In MN, the body's immune system mistakenly attacks the kidneys, causing the filters to thicken and leak protein into the urine. Over time, this can lead to serious kidney damage.
In MCD, the kidneys look nearly normal but leak large amounts of protein into the urine. Over time, this may damage the kidneys and eventually lead to kidney failure.
Adults aged 18 and older
Diagnosed with FSGS, IgAN, MN, or MCD
Evidence of proteinuria (protein in the urine)
Located in the United States and able to attend study visits
Additional criteria — including kidney biopsy results, lab values, and medical history — will be reviewed during the screening process at the clinical site. Not everyone who applies will qualify, but completing the pre-screener is a helpful first step.
A Phase 2 clinical research study is evaluating an investigational treatment for people living with rare chronic kidney diseases.
Answer a few questions online about your diagnosis and treatment history to see if you may be a match.
If you qualify, you will complete an online diagnosis-specific questionnaire to help the study team determine whether you meet the trial requirements.
If you qualify through the two-step screening process, you will be connected with a clinical site near you for in-person screening, labs, and evaluation.
If you are eligible after your in-person screening visits, you will be enrolled in the study.
Find out if you or someone you care for may be eligible for this rare chronic kidney disease research study.
CKD is a condition where the kidneys are damaged and cannot filter waste and excess fluid from the blood as well as they should. It develops slowly over time and can eventually lead to kidney failure if left untreated. There are many types of CKD, including glomerular kidney diseases.
Glomerular kidney diseases affect the tiny filtering units in the kidneys called glomeruli. When damaged, they can leak protein into the urine, and over time lead to kidney failure.
This study is investigating a new potential treatment that targets one of the underlying causes of kidney damage and protein leakage. It works in a way that is different from currently approved treatments and not yet available outside of clinical studies.
The active treatment period involves multiple doses of the investigational treatment or placebo over 3 months. After treatment, there is a 6-month follow-up period with regular visits to monitor your safety and kidney function.
No. All study-related procedures, treatments, lab tests, and visits are provided at no cost. You may be reimbursed for travel related expenses.
Yes. In most cases, you can continue your current medications as long as your doses are expected to remain stable throughout the study.
Participation is entirely voluntary. You may withdraw at any time, for any reason, without affecting your regular medical care.